Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish
Muscle & Nerve · 2024
DOI: 10.1002/mus.28047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Muscle & Nerve, 2024. Verfasst von Dong-Won Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, College of Medicine, Korea University, Ansan, Republic of Korea. Hauptthemen laut MEDLINE: Thioctic Acid, Peripheral Nervous System Diseases, Antineoplastic Agents, Thiazolidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the National Research Foundation of Korea (NRF), Korean government (MSIT), Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Introduction/Aims Oxaliplatin is a platinum‐based anti‐cancer drug widely used in colorectal cancer patients, but it may cause peripheral neuropathy. As one of the main causes of oxaliplatin‐induced peripheral neuropathy (OPN) is oxidative stress, which is also a key factor causing diabetic peripheral neuropathy (DPN), the aim of this study was to evaluate the preventive effects of alpha‐lipoic acid (ALA) and epalrestat (EP), which are used for the treatment of DPN, in an OPN zebrafish model.
Methods
Tg(nbt:dsred) transgenic zebrafish, with sensory nerves in the peripheral lateral line, were treated with oxaliplatin, oxaliplatin/EP, and oxaliplatin/ALA for 4 days. A confocal microscope was used to visualize and quantify the number of axon bifurcations in the distal nerve ending. To analyze the formation of synapses on sensory nerve terminals, quantification of membrane‐associated guanylate kinase (MAGUK) puncta was performed using immunohistochemistry.
Results
The number of axon bifurcations and intensity of MAGUK puncta were significantly reduced in the oxaliplatin‐treated group compared with those in the embryo medium‐treated group. In both the oxaliplatin/EP and oxaliplatin/ALA‐treated groups, the number of axon bifurcations and intensity of MAGUK puncta were greater than those in the oxaliplatin‐treated group ( p < .0001), and no significant difference was observed between larvae treated with oxaliplatin/ALA 1 μM and oxaliplatin/EP 1 μM ( p = .4292).
Discussion
ALA and EP have protective effects against OPN in zebrafish. Our findings show that ALA and EP can facilitate more beneficial treatment for OPN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, College of Medicine, Korea University, Ansan, Republic of Korea.
- Department of Physical Medicine and Rehabilitation, College of Medicine, Korea University, Ansan, Republic of Korea.
ORCID-Profile: Hae-Chul Park, Dong Hwee Kim
Förderung
- the National Research Foundation of Korea (NRF), Korean government (MSIT)
- Ministry of Science and ICT, South Korea
Zitieren
APA
Lee, D. W., Park, H. C., & Kim, D. H. (2024). Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish. Muscle & Nerve. https://doi.org/10.1002/mus.28047
Vancouver
Lee DW, Park HC, Kim DH. Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish. Muscle & Nerve. 2024. doi:10.1002/mus.28047
BibTeX
@article{Lee2024,
author = {Lee, Dong-Won and Park, Hae-Chul and Kim, Dong Hwee},
title = {Protective effect of alpha‐lipoic acid and epalrestat on oxaliplatin‐induced peripheral neuropathy in zebrafish},
journal = {Muscle & Nerve},
year = {2024},
doi = {10.1002/mus.28047}
}
EUVIMED